# Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

**Authors:** Barry J. Byrne, Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Paula R. Clemens, Ozlem Goker-Alpan, Xue Ming, Mark Roberts, Matthias Vorgerd, Kumaraswamy Sivakumar, Ans T. van der Ploeg, Mitchell Goldman, Jacquelyn Wright, Fred Holdbrook, Vipul Jain, Elfrida R. Benjamin, Franklin Johnson, Sheela Sitaraman Das, Yasmine Wasfi, Tahseen Mozaffar

PMC · DOI: 10.1007/s00415-025-12899-3 · 2025-02-17

## Full-text entities

- **Diseases:** Pompe disease (MESH:D006009)
- **Chemicals:** miglustat (MESH:C059896)

---
Source: https://tomesphere.com/paper/PMC11832724